Efficacy: gBRCAmut

NOVA: In the gBRCAmut Cohort, the Median PFS Was Nearly 4x Longer Than Placebo1-3

In the NOVA trial, ZEJULA Provided More Time Without Disease Progression, Independent of Baseline Patient Characteristics1,2,4

This analysis is exploratory in nature; it does not control for type 1 error and is not powered to determine treatment effect in any subgroup.1,2,4

CR, complete response; gBRCAmut, germline BRCA mutated; HR, hazard ratio; PFS, progression-free survival; PR, partial response.

References: 1. ZEJULA (niraparib) [package insert]. Waltham, MA: TESARO, Inc.; October 2019. 2. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164, and Supplementary Appendix. 3. Matulonis UA, Herrstedt J, Tinker AV, et al. Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Poster 5534. 4. Data on file. TESARO, Inc.

Efficacy data


View PFS by cohort, including non-gBRCAmut

View Efficacy
Pivotal trial


See the pivotal phase 3 trial publication

Access Publication
Back to Top